GLP-1 drugs and hair loss: what the evidence actually shows

What's this video probably claiming?

Based on the caption and hashtags, @heyhannah19 is almost certainly describing personal hair shedding while on a GLP-1 receptor agonist, probably semaglutide or tirzepatide, while being careful not to directly blame the drug. That hedging is actually more honest than most content in this space. The video likely walks through her shedding timeline, maybe shows her hairbrush or shower drain, and asks followers whether they've experienced the same thing. It probably touches on whether the drug itself is the culprit or whether something else, like rapid calorie restriction or nutritional deficiency, is the real driver. This is a genuinely common concern among GLP-1 users and one that clinical trial data does document, though the mechanism is more complicated than most TikTok creators acknowledge.

What does the science actually show?

Hair loss (medically called telogen effluvium) is listed as an adverse event in the SURMOUNT-1 trial for tirzepatide, where it was reported in approximately 5.7% of participants at the 15 mg dose versus 1% in the placebo group (Jastreboff et al., 2022, New England Journal of Medicine). The STEP 1 trial for semaglutide 2.4 mg showed similar rates, roughly 3% of participants reporting alopecia compared to under 1% on placebo (Wilding et al., 2021, NEJM). The important caveat: these trials involved significant caloric restriction alongside the drug. Telogen effluvium is a well-documented response to rapid weight loss of any kind, typically appearing two to four months after the physiological stressor. A 2017 review by Guo and Katta in Dermatology Practical and Conceptual specifically identified caloric restriction and micronutrient deficiencies, particularly iron, zinc, and biotin, as primary triggers. The drug itself may not be doing the damage directly.

Where does the social media noise diverge from clinical reality?

The loudest claim circulating on GLP-1 TikTok is that semaglutide or tirzepatide directly causes hair follicle damage, implying permanent or structural loss. That is not supported by the clinical literature. Telogen effluvium is almost universally temporary. Hair follicles enter a resting phase and then regrow, typically within six to twelve months once the triggering stressor stabilizes. What social media consistently underweights is the role of inadequate protein intake. GLP-1 drugs suppress appetite dramatically, and users eating 800 to 1,000 calories a day are often not hitting minimum protein thresholds. A 2021 paper by Cava et al. in Nutrients found that protein intake below 1.2 g per kg of body weight during caloric restriction significantly accelerated lean mass loss, which correlates with nutrient deprivation patterns that drive telogen effluvium. Blaming the drug without examining diet is a meaningful analytical gap.

What should you actually know?

If you are on a GLP-1 medication and experiencing hair shedding, a few things are worth understanding. First, the shedding is almost certainly telogen effluvium and not androgenetic alopecia or permanent follicle damage. Second, the timing matters: shedding that starts two to four months after beginning the drug or after a period of rapid weight loss fits the classic pattern and is not a red flag for permanent loss. Third, bloodwork actually helps here. Checking ferritin (not just hemoglobin), zinc, and B12 can identify correctable deficiencies that are accelerating the problem. Dermatologists and dietitians familiar with bariatric-style weight loss are better equipped to evaluate this than a general practitioner who has never managed GLP-1 patients. The creator's instinct to not definitively blame the drug is, based on the available data, more scientifically defensible than most content in this category.